Journal of investigative and clinical dentistry · 2018
Interleukin-34 levels in gingival crevicular fluid and plasma in periodontal health and disease with and without type-2 diabetes mellitus.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guruprasad C N, Pradeep A R
Аннотация
AIM: The aim of the present study was to evaluate and correlate the levels of interleukin-34 (IL-34) in gingival crevicular fluid (GCF) and plasma in chronic periodontitis (CP) patients with and without type-2 diabetes mellitus (DM).
METHODS: A total of 175 patients were divided into five groups: (a) group I had 35 periodontally-healthy patients; (b) group II had 35 chronic gingivitis patients; (c) group III had 35 CP patients without type-2 DM; (d) group IV had 35 CP patients with type-2 DM; and (e) group V had 35 type-2 DM patients without CP. The GCF and plasma levels of IL-34 were quantified using enzyme-linked immunosorbent assay. Clinical and systemic parameters, such as gingival index, probing pocket depth, clinical attachment loss, and glycated hemoglobin levels, were evaluated.
RESULTS: The mean IL-34 concentration in GCF and plasma was highest for group IV, followed by groups III, V, and II, and lowest in group I. The difference between them was statistically significant (P < .05). There was a positive correlation between IL-34 concentration in GCF and plasma in the study groups, with the exception of group I, for which there was a negative correlation.
CONCLUSION: IL-34 can be considered a possible GCF and plasma inflammatory biomarker of periodontal disease progression and DM.
METHODS: A total of 175 patients were divided into five groups: (a) group I had 35 periodontally-healthy patients; (b) group II had 35 chronic gingivitis patients; (c) group III had 35 CP patients without type-2 DM; (d) group IV had 35 CP patients with type-2 DM; and (e) group V had 35 type-2 DM patients without CP. The GCF and plasma levels of IL-34 were quantified using enzyme-linked immunosorbent assay. Clinical and systemic parameters, such as gingival index, probing pocket depth, clinical attachment loss, and glycated hemoglobin levels, were evaluated.
RESULTS: The mean IL-34 concentration in GCF and plasma was highest for group IV, followed by groups III, V, and II, and lowest in group I. The difference between them was statistically significant (P < .05). There was a positive correlation between IL-34 concentration in GCF and plasma in the study groups, with the exception of group I, for which there was a negative correlation.
CONCLUSION: IL-34 can be considered a possible GCF and plasma inflammatory biomarker of periodontal disease progression and DM.